Evidence map›Paper›PMID 40829087›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study.

Liting Zhou, Purnima Singh, David Crossman, Joshua Richman, Patrick Trainor, Changde Cheng, Xuexia Wang, Noha Sharafeldin, Lindsey Hageman, Maryam Sheikh and 10 more

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Liting ZhouUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0005-9995-6348
Purnima SinghUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-4968-7398
David CrossmanUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-0981-169X
Joshua RichmanUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-6166-7488
Patrick TrainorUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-3012-9716
Changde ChengUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-2458-2522
Xuexia WangFlorida International University, Miami, FL.
Noha SharafeldinUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-8835-8899
Lindsey HagemanUniversity of Alabama at Birmingham, Birmingham, AL.
Maryam SheikhUniversity of Alabama at Birmingham, Birmingham, AL.
Melissa A RichardBaylor College of Medicine, Houston, TX.ORCID 0000-0003-0129-9860
Danielle N FriedmanMemorial Sloan Kettering, New York, NY.ORCID 0000-0003-4668-9176
Joseph P NegliaUniversity of Minnesota Cancer Center, Minneapolis, MN.ORCID 0000-0002-5525-0598
Zhaoming WangSt Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-7556-3869
Melissa M HudsonSt Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-6984-2407
Saro H ArmenianCity of Hope National Medical Center, Duarte, CA.ORCID 0000-0003-2604-8603
Douglas HawkinsSeattle Children's Hospital, Seattle, WA.ORCID 0000-0003-3602-1375
Ravi BhatiaUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-5740-2316
Wendy LandierUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0003-3319-5652
Smita BhatiaUniversity of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-7755-5683

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
Community Clinical Oncology Program Research BaseU10CA095861 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI POLLOCK, BRAD H · 2002 to 2013
$19.5M
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer SurvivorsR35CA220502 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, SMITA · 2018 to 2024
$5.9M
Role of Genetic Susceptibility in Therapy-related Subsequent MalignanciesR01CA139633 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, SMITA · 2010 to 2014
$3.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA139633NCI NIH HHS R35 CA220502NCI NIH HHS U10 CA095861NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

purposeThere is emerging evidence that germline pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes (CPGs) increase the risk of subsequent neoplasms (SNs) in childhood cancer survivors. However, clinical application of this observation is hampered by the lack of knowledge regarding subpopulations at risk for SNs who could potentially benefit from genetic screening. PATIENTS AND

methodsWhole-exome sequencing was performed using germline DNA from 499 survivors with SNs (cases) and 625 survivors without (matched controls) in a Children's Oncology Group study. Using conditional logistic regression, we estimated demographic/clinical/therapeutic characteristics and P/LP mutations associated with SN risk. We then randomly partitioned the case-control data set using a 60/40 split to create training and test data, respectively, and developed a clinical risk classifier. Model performance and its improvement with addition of P/LP mutation status was evaluated on the test data using the area under the receiver operating curve (AUC).

resultsWe found a 4.26-fold higher odds of SNs among P/LP mutation carriers (95% CI, 2.36 to 7.69). The clinical risk classifier (including sex, primary cancer type and year of diagnosis, exposure to radiation and platinum compounds, and length of follow-up) showed a significant performance improvement with the addition of P/LP mutation status, and P/LP × platinum and P/LP × radiation interactions (AUC increased from 0.79 to 0.82,

conclusionThese findings provide a risk-based approach for identifying childhood cancer survivors who could be referred for genetic testing, informing surveillance strategies on the basis of refined risk classification.

Indexed as

Cancer SurvivorsGerm-Line MutationNeoplasmsNeoplasms, Second PrimaryAdolescentCase-Control StudiesChildChild, PreschoolExome SequencingFemaleGenetic Predisposition to DiseaseGenetic TestingHumansInfantMaleYoung Adult

Identifiers

PMID40829087
PMCPMC12367065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.